BCG Bladder Bladder Neoplams Cancer Cystectomie Cystectomy Cytologie Urinaire Cytology Medical Subject Headings (MeSH) Carcinome Urothélial Medical Subject Headings (MeSH) Urothelial Carcinoma Survie Survival Tumeurs De La Vessie Vessie.

Urothelial Carcinoma Bladder Cytology Bladder Neoplams Cancer BCG Cystectomy Survival

Humans *Carcinoma Transitional Cell/pathology *Urinary Bladder Neoplasms/genetics DNA Methylation Neoplasm Recurrence Local/genetics Prognosis *Urologic Neoplasms/genetics/pathology Membrane Proteins/genetics Neoplasm Proteins/genetics Biomarkers Kaplan-Meier survival Meta-analysis Methylation Upper tract urothelial carcinoma

Blood Transfusion/*mortality Combined Modality Therapy Cystectomy/*mortality Humans *Perioperative Care Prognosis Survival Rate Urinary Bladder Neoplasms/pathology/*therapy Bladder cancer Blood transfusion Cystectomy Meta-analysis Oncology Systematic review

Bladder cancer Intra-arterial chemotherapy Intravesical chemotherapy Recurrence Survival

Aged Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Carcinoma Transitional Cell/*drug therapy/*pathology Female Humans Immune Checkpoint Inhibitors/*therapeutic use Liver Neoplasms/secondary Male Middle Aged Survival Analysis Urinary Bladder Neoplasms/*drug therapy/*pathology bladder cancer immune checkpoint inhibitors immunotherapy meta-analysis urothelial carcinoma

Humans Immunotherapy Inflammation Prognosis Progression-Free Survival *Urinary Bladder Neoplasms

Humans *Carcinoma Transitional Cell/radiotherapy/surgery/drug therapy *Urinary Bladder Neoplasms Radiotherapy Adjuvant Retrospective Studies Prospective Studies Neoplasm Recurrence Local adjuvant radiotherapy external beam genitourinary locoregional control meta-analysis proximal ureter renal pelvis survival systematic review upper tract urothelial carcinoma

Biomarkers Humans Inflammation Prognosis Proportional Hazards Models *Urinary Bladder Neoplasms bladder cancer meta-analysis survival systemic immune-inflammation index commercial or financial relationships that could be construed as a potential conflict of interest.

bladder cancer meta-analysis smoking cessation survival systematic review

Autoantigens Biomarkers Tumor/genetics/metabolism Gene Expression Regulation Neoplastic Humans Procollagen-Lysine 2-Oxoglutarate 5-Dioxygenase/genetics/metabolism Prognosis *Urinary Bladder Neoplasms/pathology Bladder cancer Meta-analysis Microarray datasets Overall survival Prognostic biomarker

Cystectomy/*methods Humans *Margins of Excision Survival Rate Ureter/*surgery Urinary Bladder Neoplasms/mortality/*surgery Bladder cancer Cancer de vessie Cystectomie Cystectomy Examen extemporané Frozen section Recoupes urétérales Ureteral margin

Radical cystectomy bladder preservation distant metastasis rate (DMR) muscular invasive bladder cancer (MIBC) survival rate form (available at https://dx.doi.org/10.21037/tau-21-564). The authors have no conflicts of interest to declare.

Humans *Urinary Bladder Neoplasms/diagnosis/therapy/pathology BCG Vaccine/therapeutic use Cystectomy Administration Intravesical Urinary Bladder/pathology Bcg Bladder Bladder tumours Cancer Carcinome urothélial Cystectomie Cytologie urinaire Survie Survival Tumeurs de la vessie Urine cytology Urothelial carcinoma Vessie

*Carcinoma Transitional Cell/pathology/radiotherapy Humans *Kidney Neoplasms Kidney Pelvis/pathology Prognosis *Ureteral Neoplasms/pathology *Urinary Bladder Neoplasms Adjuvant radiotherapy Prognostic Radiotherapy Survival Upper urinary tract urothelial carcinoma

Cystoscopy Fluorescence Recurrence rate Recurrence-free survival Urinary bladder neoplasms

Adult Aged Aged 80 and over Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use B7-H1 Antigen/antagonists & inhibitors Carcinoma/*drug therapy/immunology/mortality/pathology Clinical Decision-Making Female Humans Immune Checkpoint Inhibitors/adverse effects/*therapeutic use Male Middle Aged Patient Selection Progression-Free Survival Time Factors Urinary Bladder Neoplasms/*drug therapy/immunology/mortality/pathology Urothelium/*drug effects/immunology/pathology Immune-checkpoint inhibitor Meta-analysis Programmed death-ligand 1 Urothelial carcinoma interests/personal relationships which may be considered as potential competing interests: The authors certify that all conflicts of interest including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the article are listed as follows: Shahrokh Shariat owns or co-owns the following patents: methods to determine prognosis after therapy for prostate cancer. Granted 2002-09-06. Methods to determine prognosis after therapy for bladder cancer. Granted 2003-06-19. Prognostic methods for patients with prostatic disease. Granted 2004-08-05. Soluble Fas: urinary marker for the detection of bladder transitional cell carcinoma. Granted 2010-07-20. He has a consulting or advisory role for the following: Astellas Astra Zeneca Bayer BMS Cepheid Ferring Ipsen Jansen Lilly MSD Olympus Pfizer Pierre Fabre Roche Sanochemia Sanofi Takeda Urogen and Wolff. All remaining authors have declared no conflicts of interest.

Aged Aged 80 and over Female Humans Male Middle Aged Neoplasm Recurrence Local/*therapy Rhabdomyosarcoma/mortality/*therapy Survival Analysis Urinary Bladder Neoplasms/mortality/*therapy Adult Bladder Rhabdomyosarcoma

Carcinoma Transitional Cell/pathology Disease-Free Survival Humans *Neoplasm Staging Prognosis Urinary Bladder/*pathology Urinary Bladder Neoplasms/*pathology Bladder urothelial carcinoma Meta-analysis Squamous differentiation

Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Carcinoma Transitional Cell/*drug therapy/pathology Clinical Trials Phase II as Topic Clinical Trials Phase III as Topic Humans Neoplasm Metastasis Neoplasm Staging Practice Guidelines as Topic Randomized Controlled Trials as Topic Urinary Bladder Neoplasms/*drug therapy/pathology Immune checkpoint inhibitors Platinum-based chemotherapy Survival outcomes Treatment guidelines Urothelial carcinoma funded this work. MK PK and SD are employees of Evidera.